甲基化
DNA甲基化
列线图
CpG站点
生物
结直肠癌
肿瘤科
比例危险模型
内科学
生存分析
癌症
基因
医学
基因表达
遗传学
作者
Hao Huang,Lei Zhang,Jinming Fu,Tian Tian,Xinyan Li,Yu-Peng Liu,Hongru Sun,Dapeng Li,Lin Zhu,Jing Xu,Ting Zheng,Jia Chen,Yashuang Zhao
摘要
Abstract Abnormal DNA methylation is considered a vital hallmark to regulate gene expression and influence the development and progression of colorectal cancer (CRC). Although CRC‐related methylation prognostic models have been developed, their clinical application is limited due to the lack of external validation and extension to other survival evaluation indicators. Therefore, this study aimed to develop and validate novel methylation prognostic models correlated with different survival indicators for individualized prognosis prediction for CRC patients. The prognostic‐related CpG sites of methylation‐driven genes screened by the MethylMix algorithm were identified and validated in The Cancer Genome Atlas (TCGA) CRC methylation data and our methylation data. The prognostic models correlated with different survival evaluation indicators (overall survival [OS] and disease‐free survival [DFS]) were developed and validated in the TCGA CRC dataset ( N = 376) and our independent CRC dataset ( N = 227). We utilized the combination of selected 3‐CpG methylation sites in three genes ( DAPP1, FAM3D , and PIGR ) to construct a prognostic risk‐score model. In the training dataset, Kaplan–Meier survival analysis demonstrated that high‐risk patients had significantly poorer survival than low‐risk patients ( p OS = .0014; p DFS < .001). Then, the 3‐CpG methylation signature was successfully validated as an independent predictor in the testing data set ( p OS = .016; p DFS = .016). A prognostic nomogram was constructed and validated. Additionally, mediation analysis revealed the direct effect of the methylation signature on CRC prognosis ( p OS = 9.149e−06; p DFS = .001). In summary, our study revealed that the 3‐CpG methylation signature might be a potential prognostic indicator to facilitate individualized survival prediction for CRC patients.
科研通智能强力驱动
Strongly Powered by AbleSci AI